All In Biotech

Drug Trial Radar · NCT00075803

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)

Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Actual

Start

Nov 2003

Primary completion

Sep 2006

Study completion Sep 2007

Sponsor

Lead sponsor
Medical College of WisconsinAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI); National Marrow Donor Program
First posted
Jan 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.

Conditions

  • Lymphoma
  • Infection
  • Leukemia

Interventions

  • FluconazoleDrug

    Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients \> 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients \< 12 years, intravenous doses will be prepared.

  • VoriconazoleDrug

    Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients \> 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients \> 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age \< 12 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplantTime frame: 180 days

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • UCSD Medical Center

    La Jolla, California

  • Stanford Hospital and Clinics

    Stanford, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • University of Florida College of Medicine (Shands)

    Gainesville, Florida

  • H. Lee Moffitt Cancer Center

    Tampa, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Indiana University Medical Center

    Indianapolis, Indiana

  • Johns Hopkins/SKCCC

    Baltimore, Maryland

  • Dana Farber Cancer Institute/Brigham & Womens

    Boston, Massachusetts

  • Dana Farber Cancer Institute/Children's Hospital of Boston

    Boston, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute/BMT

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri

  • Kansas City Cancer Centers

    Kansas City, Missouri

  • Cardinal Glennon Children's Hospital

    St Louis, Missouri

  • Washington University/Barnes Jewish Hospital

    St Louis, Missouri

  • Washington University/St. Louis Children's Hospital

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • University Hospitals of Cleveland/Case Western

    Cleveland, Ohio

  • Oregon Health Sciences University

    Portland, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pennsylvania Cancer Center

    Philadelphia, Pennsylvania

  • University of Texas/MD Anderson CRC

    Houston, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • Utah BMT/Univ of Utah Med School

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.